Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Hitz shall assume new role from January 17th, 2022
The brand is now available pan-India through their distribution partner
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Partnering to build biosynthesis processes and a pharmaceutical production platform
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
